Other sections explore therapeutic strategies targeting inflammatory pathways and the role of immunometabolism and discuss biomarker discovery and personalized treatment plans. The final section examines the tumor microenvironment, the microbiome's role, and the intersection of immunotherapy and inflammation. The book offers numerous benefits to its audience. For scientists and researchers, it provides cutting-edge knowledge to inspire new research directions and foster interdisciplinary collaboration while serving as a valuable educational tool for the next generation of researchers.
Table of Contents
Section I. Foundational Concepts1. Introduction
2. Recent Advances and Future Research Directions in the Crosstalk Between Inflammation and Tumors
Section II. Signaling Pathways and the Dynamics
3. Signaling Pathways, Inflammatory Mediators, and Oncogenesis
Section III. Translational Research and Therapeutic Targets
4. Targeting Inflammatory Pathways for Cancer Therapy
5. Immunometabolism and Its Implications for Cancer Research
6. Emerging Technologies and Future Research Directions in Inflammation and Cancer Research
Section IV. Biomarkers and Personalized Medicine
7. Biomarker Discovery and Validation in Inflammatory Cancer Research
8. Personalized Medicine Utilizing Biomarkers
Section V. Clinical Implications and Therapeutic Strategies
9. Inflammation and Tumor Microenvironment
10. The Microbiome's Role in Systemic Inflammation, Immune Responses, and Tumor Microenvironment
11. Immunotherapy and Inflammation Management
Authors
Chunxiang Zhang Deputy Secretary of the Party Committee and President of Southwest Medical University; Director of the Key Laboratory of the Ministry of Education, China. Dr. Chunxiang Zhang is a distinguished cardiologist and academic leader with extensive international experience in cardiology and oncology. He holds a Doctor of Cardiology degree and completed his postdoctoral fellowship in cardiovascular pharmacology in the US. Currently serving as the Deputy Secretary of the Party Committee and President of Southwest Medical University, he also directs the Key Laboratory of the Ministry of Education. His career spans over three decades, including ten years in top cardiology departments in China and 22 years in the US, where he held prestigious positions at the University of Tennessee and Rush University. Dr. Zhang's research delves into the molecular mechanisms of tumorigenesis, inflammation, and cancer therapies, with notable work on tetraspanins in digestive system cancers and innovative therapeutic strategies. His comprehensive research and publications provide valuable insights into signaling pathways, biomarkers, and clinical implications, making him a key figure in advancing cancer treatment and understanding. Mowei Kong Researcher, Southwest Medical College, China.Dr. Mowei Kong, MD, is a seasoned medical professional with a rich background in endocrinology, metabolism, oncology, and cardiovascular diseases. He previously served as a clinical physician at Guiqian International Hospital and is currently engaged in basic research at Southwest Medical College. Dr. Kong's expertise spans Type 2 Diabetes, insulin resistance, obesity, gastrointestinal and cardiac tumors, and coronary heart disease. Some notable works include studies on CTRP6's role in digestive system tumors and GLP-1 receptor agonists' effects on lipotoxicity.
His experience in these areas highlights his ability to analyze signal transduction pathways, identify new therapeutic targets, and translate basic scientific research into clinical applications. Dr. Kong's comprehensive experience in both clinical practice and research enables him to provide valuable insights and advancements in the understanding and treatment of cancer and related conditions.
